Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI) is a pharmaceutical company focused on the development and commercialization of novel therapies for cancer and other diseases. The company is known for its pioneering work in nuclear export inhibition, particularly through its lead product, selinexor, which is used to treat multiple myeloma and certain other hematologic cancers. Karyopharm’s approach involves targeting the nuclear export pathway to reactivate tumor suppressor proteins and enhance cancer cell death.
Company News
Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma, a blood cancer affecting over 176,404 people worldwide. This year, the International Myeloma Foundation invites individuals to share their most meaningful myeloma milestones, celebrating resilience, ...
Karyopharm Therapeutics (KPTI) has been beaten down lately, but the stock is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier, indicating a potential turnaround.
KPTI earnings call for the period ending March 31, 2024.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?